Angela Fleischman

If you are in SoCal, consider joining us @HiltonHB on Saturday, 1/19 to hear what colleagues and I from @ucirvinehealth and @chocchildrens think may be practice-changing from #ASH18. @MOASC_Office will provide CME credit and cocktails for your time! files.constantcontact.com/b40a8491101/cd…

#ASH18 | Congratulations 🎉🎈🎊 to Dr Angela Fleischman @MPNlab winning #MPNHero award! @cure_magazine @mpncare @doctorpemm @ScottHamilton84 | @MPN_RF @mpnadvocacy @PatientPower @andrewschorr @PVReporter @mpndoc @AaronGerds @lauracmichaelis @mpdrc @RobynScherber | #MPNSM

@OncologyTimes A5: Identification of more tumor associated antigens such as the novel peptide generated from calreticulin mutation in myeloproliferative neoplasm would be ideal targets. #HemOncChat

Q5: Where do you see CAR T-cell therapy expanding in the next 5 years? #CARTcell #HemOncChat

@OncologyTimes A4: Immunotherapy at the present time is not a replacement for transplantation but can put someone in a CR such that they can move on to transplant. #HemOncChat

There’s still time to JOIN our #HemOncChat with Dr. Angela Fleischman. Here's Q4: How does immunotherapy work with hematopoietic stem cell transplantation? #stemcells

@OncologyTimes A4: Immunotherapy such as CAR-T cells can be used as a bridge to transplant. #HemOncChat

@OncologyTimes A5: I see it expanding to more novel targets in both solid and hematologic malignancies. #HemOncChat

@OncologyTimes A3: Many new and exciting immunotherapy combinations are being investigated, but it is important to note that combos may increase response rates but also may add on additional toxicities as well as cost. #HemOncChat

Q3: How will combination immunotherapy play a role in future treatments? #HemOncChat

@OncologyTimes A3: Combination therapies using a PD-1 pathway inhibitor are currently utilized and have proven to be useful and new combos will likely to be developed with PD-1 inhibitors. #HemOncChat

@OncologyTimes A2: Proteins that are present on tumor cells but not normal cells are ideal targets for immunotherapies such as CAR-T cell therapy. The calreticulin mutations in myeloproliferative neoplasm generates a novel peptide unique to the mutant cells which is ideal target. #HemOncChat

Q2: What area of hem/onc will be most affected by immunotherapy advances? #HemOncChat

@OncologyTimes A2: Within the hematologic malignancies lymphoid malignancies appear to be particularly amenable to immunotherapies. Within the solid tumors lung and melanoma appear to be particularly amenable to immunotherapies. #HemOncChat

@OncologyTimes A1: The third unique feature is established cell surface antigens to target. #HemOncChat

Let’s begin with Q1: What are novel aspects of #Immunotherapy in hematologic malignancies? #HemOncChat

@OncologyTimes A1: Second is cells of the immune system and hematologic malignancy cells are in constant contact with each other within the hematopoietic system, making the environment conducive to constant immune surveillance. #HemOncChat

@OncologyTimes A1: There are some unique features of hematologic malignancies that makes them cancers particularly well suited as targets of immunotherapy. First is sensitivity to immune attack. #HemOncChat

#Trametinib Early Study Shows Impressive Results for #MPN ow.ly/tPxq309rJpy @MPNlab @MOASC_Office #CancerResearch #MPNs #mpnsm #ASH

The importance of non-pharmacological interventions in myeloproliferative neoplasms by Ruben Mesa vjhemonc.com/video/zqzcbkp8… via @VJHemOnc

@doctorpemm #MPN clinical trial now open, LCL-161 makes cells sensitive to killing by TNFalpha clinicaltrials.gov/ct2/show/NCT02…

#ASH2014 mutated calreticulin in mouse model causes a disease resembling ET/MF ash.confex.com/ash/2014/webpr…

#ASH14 My first tweet! Follow me for updates in MPN translational research. Inspired to start tweeting by @doctorpemm